Parathyroid hormone treatment for glucocorticoid-induced osteoporosis

Nancy E Lane, Q. Rehman

Research output: Contribution to journalArticlepeer-review


Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Issue number5 SUPPL. 21
StatePublished - 2000
Externally publishedYes


  • Glucocorticoid-induced osteoporosis
  • Human parathyroid hormone (hPTH) (1-34)

ASJC Scopus subject areas

  • Immunology
  • Rheumatology


Dive into the research topics of 'Parathyroid hormone treatment for glucocorticoid-induced osteoporosis'. Together they form a unique fingerprint.

Cite this